CYTOTOXICITY OF THE ANTICANCER AGENTS CISPLATIN AND TAXOL DURING CELL-PROLIFERATION AND THE CELL-CYCLE

被引:193
作者
DONALDSON, KL [1 ]
GOOLSBY, GL [1 ]
WAHL, AF [1 ]
机构
[1] BRISTOL MYERS SQUIBB PHARMACEUT RES INST, SEATTLE, WA 98121 USA
关键词
D O I
10.1002/ijc.2910570614
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The overt effects of the anti-cancer drugs cisplatin (cis-DDP) and taxol appear to be DNA modification and microtubule stabilization respectively, yet the mechanisms by which these drugs elicit tumor cell death are not well understood. In this report cell sensitivities to cis-DDP and taxol were accurately determined as a function of cell proliferation and cell cycle stage. Quiescent fibroblasts restimulated to synchronously enter the cell cycle become maximally sensitive to cis-DDP immediately preceding DNA synthesis, and resistance increases with onset of DNA synthesis. Mid-log proliferating cells were separated into progressive stages of the cell cycle by centrifugal elutriation or by double thymidine (dThd) block. Cells staged by either method are maximally sensitive to cis-DDP in G(1), just prior to the onset of DNA synthesis and minimally sensitive in peak DNA synthesis, with entry into S phase resulting in a 2-fold decrease in sensitivity. Cells that remained blocked at the G(1)/S phase boundary during cis-DDP treatment remain maximally sensitive after release. Sensitivity to taxol increases at 2 points: transiently during transition of normal cells from quiescence to proliferation and steadily as proliferating cells progress from early G(1) to late G(2). This 3-fold increase in taxol sensitivity through the cell cycle is rapidly reversed upon cell division. Synchronous cells treated with either drug at points of maximum sensitivity initiate apoptotic DNA fragmentation 12-14 hr post-exposure to drug. (C) 1994 Wiley-Liss, Inc.
引用
收藏
页码:847 / 855
页数:9
相关论文
共 36 条
  • [1] BARCELLOSHOFF MH, 1990, CANCER RES, V50, P3551
  • [2] BARRY MA, 1993, CANCER RES, V53, P2349
  • [3] BJURSELL G, 1973, J BIOL CHEM, V248, P3904
  • [4] CLINICAL-PHARMACOLOGY OF HIGH-DOSE CISPLATIN
    CORDEN, BJ
    FINE, RL
    OZOLS, RF
    COLLINS, JM
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1985, 14 (01) : 38 - 41
  • [5] MICROTUBULE STABILIZATION BY TAXOL INHIBITS INITIATION OF DNA-SYNTHESIS BY THROMBIN AND BY EPIDERMAL GROWTH-FACTOR
    CROSSIN, KL
    CARNEY, DH
    [J]. CELL, 1981, 27 (02) : 341 - 350
  • [6] EINZIG A I, 1990, Proceedings of the American Association for Cancer Research Annual Meeting, V31, P187
  • [7] FRAVAL HNA, 1979, CANCER RES, V39, P1793
  • [8] DEFECTS IN A CELL-CYCLE CHECKPOINT MAY BE RESPONSIBLE FOR THE GENOMIC INSTABILITY OF CANCER-CELLS
    HARTWELL, L
    [J]. CELL, 1992, 71 (04) : 543 - 546
  • [9] EFFECT OF THE ANTITUMOR DRUG CIS-DIAMMINEDICHLOROPLATINUM(II) AND RELATED PLATINUM COMPLEXES ON EUKARYOTIC DNA-REPLICATION
    HEIGERBERNAYS, WJ
    ESSIGMANN, JM
    LIPPARD, SJ
    [J]. BIOCHEMISTRY, 1990, 29 (36) : 8461 - 8466
  • [10] PHASE-II TRIAL OF TAXOL, AN ACTIVE-DRUG IN THE TREATMENT OF METASTATIC BREAST-CANCER
    HOLMES, FA
    WALTERS, RS
    THERIAULT, RL
    FORMAN, AD
    NEWTON, LK
    RABER, MN
    BUZDAR, AU
    FRYE, DK
    HORTOBAGYI, GN
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (24) : 1797 - 1805